An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients.

ABSTRACT: Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), has been presented as a broad-spectrum antiviral agent. This randomised clinical trial in a hospital setting evaluated the efficacy and safety of this drug in RT-PCR-positive coronavirus disease 2019 (COVID-19) patients. A total of 210 RT-PCR-positive COVID-19 patients who provided consent were allotted to the control or case arm, based on block randomisation. The control arm received standard of care comprising paracetamol, ivermectin, and other adjuvant therapies. The patients in the case arm received indomethacin instead of paracetamol, with other medications retained. The primary endpoint was the development of hypoxia/desaturation with SpO₂ ≤ 93, while time to become afebrile and time for cough and myalgia resolu

SUBMITTER: Ravichandran R 

PROVIDER: S-EPMC9016692 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature